Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CV Therapeutics submits regadenoson

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

CV Therapeutics submits regadenoson: CV Therapeutics and Astellas submit an NDA for their novel cardiac imaging stress agent regadenoson May 14. The application is supported by two Phase III trials, which demonstrated noninferiority compared to Astellas' currently marketed stress agent Adenoscan (adenosine). CVT is highlighting a potential safety benefit for regadenoson over competing stress agents, including the market leader Adenoscan (1Pharmaceutical Approvals Monthly May 2005, p. 12). The filing triggers a $7 million payment from Astellas to CVT; upon approval CVT would receive another $12 million. CVT is also in the process of reshaping its sales force and curtailing R&D expenses to focus on a label expansion of its second-line angina drug Ranexa (ranolazine) and to launch regadenoson in mid-2008 following approval...

You may also be interested in...



CVT Plans Regadenoson NDA Submission As Cardiac Stress Agent For 2006

CV Therapeutics expects to wrap-up two Phase III trials of its selective A2A-adenosine receptor agonist regadenoson (CVT-3146) in the third and fourth quarters, in time for a 2006 NDA submission

With US Respiratory Pipeline Unlocked, Cipla Wants Lung Leadership

Cipla sees an incremental revenue opportunity of up to $500m for its US franchise by fiscal 2025 and expects to propel growth with strong execution of its complex generics pipeline. The company is also beginning to “lay the blueprint” in China and Brazil, it said at the J.P. Morgan Healthcare Conference.

Teva CEO Schultz: ‘Proof Is In The Pudding’ For US Biosimilars

Teva CEO Kåre Schultz believes his prediction is coming true for the Truxima biosimilar in-licensed from Celltrion, as he gave the latest update on Teva’s efforts to settle significant legal issues around the US opioid crisis.

UsernamePublicRestriction

Register

LL033172

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel